Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
News|Podcasts|August 8, 2022
Pharmacy Focus: Move the Needle Monday- COVID-19 Extended as Public Health Emergency
With limited supply to immunization options for monkeypox, polio, and influenza, the future of vaccine distribution will have to change.
Advertisement
In this month's episode, Ed Cohen and John Beckner from NCPA discuss the HHS's decision to extend the COVID-19 Public Health Emergency (PHE), meaning Americans can continue utilizing Medicaid benefits and telehealth services that were expanded under the PHE, updates with the Novavax COVID-19 vaccine, and the future of the monkeypox virus.
Advertisement
Related to this article
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
3
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5